Valneva SE (EPA:VLA)
2.652
-0.025 (-0.93%)
Nov 12, 2026, 9:24 AM CET
Valneva SE Revenue
Valneva SE had revenue of 34.94M EUR in the quarter ending June 30, 2026, a decrease of -27.71%. This brings the company's total for the last twelve months to 142.94M, down -27.19% year-over-year. In the year 2025, Valneva SE had annual revenue of 174.66M with 3.00% growth. That makes Valneva SE the 19,178th largest company in the world by revenue and 275th in France.
Revenue (ttm)
142.94M
Revenue Growth
-27.19%
P/S Ratio
3.56
Revenue / Employee
230.55K
Employees
620
Market Cap
504.56M
Revenue by Geography
- United States 53.61M 30.7%
- Canada 30.13M 17.2%
- Germany 17.47M 10.0%
- France 14.67M 8.4%
- Nordics 13.90M 8.0%
- Other Europe 13.88M 7.9%
- United Kingdom 12.64M 7.2%
- Other 18.37M 10.5%
Fiscal year ended Dec 31, 2025 See the full Valneva SE breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 174.66M | 5.08M | 3.00% |
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Genfit | 59.49M |
| Cellectis | 55.86M |
| MedinCell | 24.28M |
| Nanobiotix | 11.51M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
| Valerio Therapeutics Société anonyme | 5.55M |
Valneva SE News
- 2 days ago - Valneva Reports Five-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ - Nasdaq
- 2 days ago - Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 3 days ago - Valneva Reports Positive Mid-Stage Results For Shigella Vaccine Candidate S4V2 - Nasdaq
- 3 days ago - Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 7 days ago - Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026 - GlobeNewsWire
- 4 weeks ago - Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences - GlobeNewsWire
- 5 weeks ago - UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide - Nasdaq
- 5 weeks ago - Valneva announces Ixchiq marketing authorization revoked by UK MHRA - TheFly